Glyco-biomarker discovery platforms at CD BioGlyco are able to process various biological samples, and the optimized technology platforms can achieve ultra-high precision to help customers advance projects more accurately and quickly. We have the confidence to provide our customers with the optimal scientific services.
Protein glycosylation is a common post-translational modification sensitive to changes in the cellular environment. Glycosylation plays an important role in most life processes, such as protein folding, cell-to-cell interactions, receptor binding, etc. Abnormal glycosylation is associated with many diseases, including cancer, Parkinson's disease and cardiovascular disease. Glycans are different from nucleic acids and proteins as genetic templates do not directly encode them. Instead, they are dynamically assembled in hundreds of enzymes through more than a dozen complex biosynthetic pathways. Any influence on enzyme activity or any environmental changes will interfere with the final structure of glycans. Ample evidence has demonstrated the presence of abnormal N-glycosylation patterns on tumor cells, and these findings have inspired the search for glycan-based biomarkers in biological samples such as serum and plasma.
Glycans can represent biomarkers, indicating diseases with high sensitivity and specificity, and show great promise in distinguishing between healthy and diseased individuals. However, due to the need for complex sample preparation, the current methods for analyzing glycans are not suitable for clinical laboratories. Levels of complexity associated with protein glycosylation are hindering its development. To transfer the valuable knowledge provided by protein glycosylation to the clinical application, advanced strategies are needed to cope with challenges such as sample preparation, sample throughput, expensive instrumentation, and difficult data analysis.
Fig.1 Glycan biomarkers discovery unmet clinical needs. (Shipman, 2020)
CD BioGlyco is experienced in the discovery, validation, and verification of glycan biomarkers. Our technology platforms combine traditional and new technologies to achieve ultra-sensitive detection capabilities, which can be used for single-factor and multi-factor detection of a variety of biological substrates.
CD BioGlyco offers alpha-fetoprotein (AFP) detection services to help our clients diagnose hepatocellular carcinoma.
CD BioGlyco offers the glyco-biomarker CA19-9 detection services through multiple methods to help researchers diagnose and treat pancreatic cancer.
CD BioGlyco offers sensitive, reliable and rapid strategies to detect CA125, a glyco-biomarker indicative of ovarian cancer.
CD BioGlyco has developed multiple simple and cost-effective strategies for the detection of glyco-biomarkers CA15-3 for the initial screening of tumors.
CD BioGlyco offers services to detect glyco-biomarker CEA as an aid to the diagnosis, efficacy, and prognosis of gastrointestinal cancers.
CD BioGlyco provides our customers with rapid and inexpensive PSA detection, which is important for screening and monitoring prostate cancer.
CD BioGlyco developed a variety of real-time and reliable technologies such as LC-MS and HILIC-UPLC for IgG detection.
CD BioGlyco offers Hp detection services through sensitive sensor-based detection methods, providing a powerful tool for clinical diagnosis.
Based on advanced technology platforms, CD BioGlyco offers A1AT detection services for the diagnosis and treatment of A1AT deficiency (AATD).
CD BioGlyco developed a highly sensitive glyco-biomarker AGP assay platform to help our clients monitor the severity of the disease.
CD BioGlyco provides various strategies for CP detection to assist customers in the diagnosis of Wilson disease and other related diseases.
CD BioGlyco provides first-class glycan biomarker discovery platforms to process various types of biological samples. We do our best to help customers with biomedical transformation and our broad vision will provide customers with high-quality technical support. If you are interested in our services, please contact us for more detailed information.